华东医药(000963.SZ)：注射用HDM2017获得药物临床试验批准通知书

Core Viewpoint - East China Pharmaceutical (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Sino-American East Pharmaceutical Co., Ltd. (referred to as "Sino-American East"), has received the Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) for the clinical trial application of HDM2017 [1] Group 1 - HDM2017 is designed to specifically target CDH17 positive tumor surface antigens through antibody-mediated internalization, allowing the ADC to enter tumor cells and release toxic payloads to exert anti-tumor effects [1] - Preclinical studies indicate that HDM2017 demonstrates good drug-like properties, safety, and efficacy [1] - HDM2017 has shown strong anti-tumor effects in efficacy models for colorectal cancer, pancreatic cancer, and gastric cancer, and has good tolerance in animal trials [1]